Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 172 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: APS Clear all
Completed Phase 2 Interventional Results available

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

NCT01314118
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
abiraterone acetate in combination with prednisone
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
45
States / cities
Homewood, Alabama • Huntsville, Alabama • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Not listed Phase 2 Interventional

Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer

NCT00731848
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate liquid extract
Dietary Supplement
Lead sponsor
Roll International Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 29, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

NCT01681433
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA
Interventions
OGX-427, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Costantine Albany
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
Marina del Rey, California • Bloomington, Indiana • Goshen, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

TKI258 in Castrate Resistant Prostate Cancer

NCT00831792
View directory record Official record
Conditions
Prostate Cancer
Interventions
TK1258
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 29, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

NCT03230097
View directory record Official record
Conditions
Psychotic Disorders
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
16 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Culver City, California • San Diego, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 29, 2026, 5:00 PM EDT
Active, not recruiting No phase listed Observational

Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

NCT03957252
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Screening, Performance Assessment of Novel Test
Interventions
Not listed
Lead sponsor
Nanostics
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
42
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Recruiting No phase listed Observational

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

NCT00482794
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

RYZ711 Diagnostic Platform Study

NCT07862582
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions
RYZ711, PSMA PET/CT
Drug · Diagnostic Test
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Not applicable Interventional

The Utility of Pretracheal Stethoscope in Detecting Respiratory Abnormalities in Sedated Children

NCT01957566
View directory record Official record
Conditions
Sedation
Interventions
APS
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
2 Years to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

NCT00450463
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

NCT02297412
View directory record Official record
Conditions
Acute Pain, Breast Carcinoma, Peripheral Neuropathy
Interventions
Minocycline Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

NCT00148772
View directory record Official record
Conditions
Prostate Cancer
Interventions
Erlotinib (Tarceva)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 29, 2026, 5:00 PM EDT
Completed No phase listed Observational

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

NCT07477756
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Withdrawn Not applicable Interventional

Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer

NCT03823001
View directory record Official record
Conditions
Prostate Cancer
Interventions
virtual biopsy (VB) monitoring protocol
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

NCT01487863
View directory record Official record
Conditions
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
sipuleucel-T, abiraterone acetate
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
21
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

ArtemiCoffee in Patients With Rising PSA

NCT05478239
View directory record Official record
Conditions
Prostate Cancer
Interventions
ArtemiCoffee
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chromosome 18 Clinical Research Center

NCT00227253
View directory record Official record
Conditions
Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions
Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2040
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 29, 2026, 5:00 PM EDT
Recruiting Phase 4 Interventional

Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen

NCT05512754
View directory record Official record
Conditions
Elevated Serum PSA
Interventions
Ibuprofen 400 mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 29, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels

NCT00031746
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy protein isolate, casein proteins
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
50 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Syracuse, New York • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 29, 2026, 5:00 PM EDT